Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

2 of 2 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 4

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 4(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials

NCT04747314Phase 2Completed

Treating Negative Affect in Low Back Pain Patients

Role: lead

NCT07133139Not ApplicableRecruiting

Treatment Validation for Myofascial Pain

Role: lead

NCT04236804Not ApplicableCompleted

VANISH for Chronic Low Back Pain

Role: lead

NCT03588806Phase 4Terminated

Use of Xtampza ER to Overcome Difficulties in Swallowing Opioid Pills

Role: lead

All 4 trials loaded